Destiny Pharma plc
("Destiny Pharma" or the "Company")
Directors Dealings
Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following Directors' dealings:
Nick Rodgers, Chairman, purchased 9,000 Ordinary Shares at a price of 88.0p per Ordinary Share. Following the transaction, his total beneficial interest is 47,462 Ordinary Shares, representing 0.08% of the total issued share capital of the Company.
�
Details of the full notification received by the Company are set out below:
�
| 1.��������������� | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Nick Rodgers |
| 2.��������������� | Reason for the Notification | |
| a) | Position/status | Chairman |
| b) | Initial notification/Amendment | Initial notification |
| 3.���� | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4.���� | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1 pence each in Destiny Pharma Plc |
| Identification code | DEST� ��� GB00BDHSP575 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | 88.0 pence�per Ordinary Share 9,000� Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price | � See 4c) above� � |
| e) | Date of the transaction | 6 January 2021 |
| f) | Place of the transaction | London Stock Exchange, AIM Market |
�
Enquiries:
| Destiny Pharma plc | +44 (0) 1273 704 440 |
| Neil Clark (Chief Executive Officer) | |
| finnCap Limited - Nominated Adviser and Joint Broker | +44 (0) 20 7220 0500 |
| Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance) | |
| WG Partners LLP - Joint Broker | +44 (0) 20 3705 9330 |
| Nigel Barnes / Claes Sp�ng / Nigel Birks / Andrew Craig | |
| Optimum Strategic Communications | +44 (0) 203 174 1789 |
| Mary Clark / Shabnam Bashir / Manel Mateus � � | |
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of�C. difficile�infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
�
For further information, please visit�https://www.destinypharma.com
�